KDM1A and acute myeloid leukemia: To date, several LSD1 inhibitors have been approved, and some of them, including ORY-1001, GSK-2879552, IMG-7289, INCB059872, CC-90011, and ORY-2001 (See Figure 1), are currently being studied in clinical trials for cancer treatment, particularly in small lung cancer cells (SCLC) and acute myeloid leukaemia (AML) [9].